Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
Become a Member | Sign in
Home>News>This Article

GSK and the Bill & Melinda Gates Foundation to Accelerate Research into Vaccines

Published: Wednesday, October 30, 2013
Last Updated: Wednesday, October 30, 2013
Bookmark and Share
The joint initiative will endeavour to make vaccines more resistant to heat, thus reducing the need for refrigeration.

Vaccine Discovery Partnership (VxDP) announcement at the Foundation’s Grand Challenges Meeting in Rio de Janeiro signals commitment to find solutions to the challenges facing the developing world

GSK and BMGF will invest a combined $1.8 million in early stage research into vaccine thermostability.

Most vaccines must be kept cold and transported under constant refrigeration via a so-called ‘cold chain’ which is a significant challenge in hot, remote and resource-limited regions.

Details of the Vaccine Discovery Partnership (VxDP) under which this initiative falls were unveiled this morning at the Foundation’s Grand Challenges Meeting in Rio de Janeiro, Brazil. In one of the first projects to start under this initiative, GSK researchers will explore how to make adjuvants – a critical component of some vaccines – more heat stable.

“Developing a thermostable adjuvant is an important and ambitious goal. This partnership is the starting point for research into an exciting area of biomedical technology that has the potential to overcome a significant and long-standing barrier to vaccine access in developing countries,” commented Emmanuel Hanon, Senior Vice President, Vaccine Discovery and Development, GSK. “At GSK, we believe that by working together we will find innovative solutions to the world’s biggest health problems.”

This project will focus initially on the adjuvant AS01 which is used in GSK’s RTS,S malaria vaccine candidate, currently in late-stage development in partnership with the PATH Malaria Vaccine Initiative. RTS,S has been designed for use in infants and children from sub-Saharan Africa, where maintaining vaccines at an optimum temperature can be challenging. Developing a method of making AS01 more heat stable could bring a significant public health benefit. The results could also have broader applications for all other AS01-containing vaccines, including vaccines in development by GSK against HIV and tuberculosis.

“Vaccines are one of the most powerful tools to save and improve lives, and this partnership with GSK will help drive research and development efforts to overcome persistent global health challenges,” said Trevor Mundel, president of Global Health at the Bill & Melinda Gates Foundation. “Reducing the dependence on the cold chain is critical to the affordable delivery of life-saving vaccines to the children who need them most.”

Despite significant progress over the last decade, over 22 million children in developing nations remain without access to life-saving vaccines. Reducing dependence on the cold chain is a key approach to support the effective and affordable delivery of vaccines for global health.

The VxDP, instigated by the BMGF, aims to integrate key players in vaccine development – biotechnology institutions, pharmaceutical companies, non-government organisations (NGOs) and academia – to drive advances in vaccine research and development (R&D) that have the potential to transform global health. Projects funded through the VxDP will look to solve some of the world’s most intractable health problems, including barriers to vaccine access.

GSK is in on-going discussions with the Foundation to shape and plan additional projects with relevance to global health that can be initiated through this new collaboration.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

GSK, Francis Crick Institute Collaborate
This partnership sets out to explore new avenues of medical research and drug discovery across a broad range of diseases, with a view to achieving breakthroughs in the understanding of human disease.
Monday, July 20, 2015
GSK to Invest £200 Million in UK Manufacturing
The series of investments will support the delivery of the company’s pipeline of new medicines and create a centre for pharmaceutical manufacturing innovation in the UK.
Thursday, December 12, 2013
Malaria Vaccine Could be Available from 2015
GSK candidate reduces disease over 18 Months of follow-up in late-stage study of more than 15,000 infants and young children.
Tuesday, October 08, 2013
Scientific News
Drug May Prevent Life-Threatening Muscle Loss in Advanced Cancers
New data describes how an experimental drug can stop life-threatening muscle wasting (cachexia) associated with advanced cancers and restore muscle health.
Chemical Design Made Easier
Rice University scientists prepare elusive organocatalysts for drug and fine chemical synthesis.
Nanocarriers May Carry New Hope for Brain Cancer Therapy
Berkeley lab researchers develop nanoparticles that can carry therapeutics across the brain blood barrier.
Potential Persistent Tuberculosis Treatment
Researchers have discovered several first-in-class compounds that target hidden TB infections by attacking a critical process the bacteria use to survive in the hostile environment of the lungs.
Shedding Light on “Dark” Cellular Receptors
UNC and UCSF labs create a new research tool to find homes for two orphan cell-surface receptors, a crucial step toward finding better therapeutics and causes of drug side effects.
Giant Molecules Inhibit Ebola Infection
European researchers have designed a "giant" molecule formed by thirteen fullerenes covered by carbohydrates which, by blocking this receptor, are able to inhibit the cell infection by an artificial ebola virus model.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Fighting Pain with Ketamine
Researchers at the Texas A&M Health Science Center are using ketamine, a drug that already exists as an anesthetic, to treat pain.
Possible New Treatment for Neurodegenerative Diseases Found
Researchers at the University of Liverpool have found that a well-established anti-epileptic drug could also be used as a treatment for neurodegenerative diseases.
Breast Cancer Drug Beats Superbug
Tamoxifen helps white blood cells clear multidrug-resistant bacteria in lab and mouse studies.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos